Drug Profile


Alternative Names: MitoQ; MitoQ10; Mitoubiquinone

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Antipodean Pharmaceuticals
  • Class Benzoquinones; Organophosphorus compounds
  • Mechanism of Action Antioxidants; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatic fibrosis; Non-alcoholic fatty liver disease
  • Discontinued Alzheimer's disease; Cancer; Chemoprotection; Diabetes mellitus; Friedreich's ataxia; Hypertension; Ischaemia; Parkinson's disease; Retinal disorders

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-II for Non-alcoholic fatty liver disease in United Kingdom (PO)
  • 22 Sep 2015 No recent reports on development identified - Phase-II for Hepatic fibrosis (Prevention) in New Zealand (PO)
  • 03 Jun 2008 US FDA approves IND application for mitoquinone in Liver diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top